Receipt of the observation letter from BSE Limited conveying ''no adverse observations'' in relation to the Scheme of Amalgamation of Dr. Agarwal''s Eye Hospital Limited and Dr. Agarwal''s ....
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Agarwal's Eye Hospital Ltd (AEHL, scrip code 526783) has received a 'no adverse observations' letter from BSE Ltd dated February 17, 2026, for its proposed Scheme of Amalgamation with Dr. Agarwal's Health Care Limited (AHCL) under Sections 230–232 of the Companies Act, 2013. AEHL is the Transferor Company and AHCL is the Transferee Company. SEBI had already given its observations on the scheme on February 13, 2026. The Board had approved the scheme on August 27, 2025. The scheme is now ready to be filed with the National Company Law Tribunal (NCLT) within the 6-month validity of the observation letter (by approximately August 17, 2026). The deal still needs approvals from NCLT, shareholders, and creditors of both companies. Specific share swap ratio has not been disclosed in this filing.
This is a group-level amalgamation between two related Dr. Agarwal's entities, so day-to-day operations and the retail shareholder base remain largely unaffected. Once NCLT, shareholder, and creditor approvals are secured, AEHL shareholders will be issued shares in AHCL in exchange, effectively making AHCL the surviving listed entity. Short-term stock price impact is likely limited; watch for the next update disclosing the share swap ratio and the NCLT filing timeline.